Thyrocare Technologies has appointed M/s. Price Waterhouse Chartered Accountants LLP as its statutory auditor for a term of five years, effective from the conclusion of the 26th Annual General Meeting (AGM) held on June 30, 2026. The appointment, approved by the company's shareholders, will remain in force until the conclusion of the 31st AGM scheduled for the calendar year 2031. This change follows the completion of the first term of the previous statutory auditor, M/s. M S K A & Associates LLP, at the conclusion of the 26th AGM on June 30, 2026.

The company submitted the intimation to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made pursuant to a previous intimation dated May 07, 2026, and based on the Scrutiniser's Report from the AGM.

M/s. Price Waterhouse Chartered Accountants LLP holds ICAI Firm Registration No. 012754N/N500016. The firm was established in 1991 and converted into a limited liability partnership in 2014. Its registered office is located at Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi - 110 002, and it operates 17 branch offices across various cities in India.

The firm is a member of Price Waterhouse & Affiliates, a network of distinct and independent Indian Chartered Accountant firms registered with the Institute of Chartered Accountants of India (Network Registration No. NRN/E/14). As of December 31, 2025, the firm employs more than 125 Assurance Partners and holds a valid peer review certificate, auditing various listed companies in India.

Thyrocare Technologies acknowledged the contributions of the outgoing auditor, M/s. M S K A & Associates LLP (ICAI Firm Registration No. 105047W/W101187), and placed on record its appreciation for their services during their tenure. The detailed disclosures required under the SEBI Master Circular No. HO/49/14/14(7)2025-CFDPD2/I/3762/2026 dated January 30, 2026, have been provided in Annexure A to the filing.

Auditor Details

Thyrocare Technologies Limited has recommended a final dividend of Rs. 7.00 per equity share for the financial year ended March 31, 2026. The dividend is payable to shareholders whose names appear in the Register of Members on the record date of Tuesday, June 23, 2026, subject to shareholder approval at the Annual General Meeting on June 30, 2026. This final dividend is in addition to the interim dividend of Rs. 7.00 per share declared on October 14, 2025.

Under the Income Tax Act, 2025, the company is required to deduct tax at source at applicable rates. For resident shareholders with a valid PAN, the TDS rate is 10%. However, TDS will not apply if the aggregate dividend distributed to a resident individual during the Tax Year 2026-27 does not exceed Rs. 10,000. A higher rate of 20% applies if the PAN is invalid, inoperative, or not linked with Aadhaar.

Shareholders can avail of lower or nil TDS by submitting specific forms. Residents may submit Form 121 or a certificate under Section 395(1) of the Act. Exempt entities such as insurance companies, mutual funds, and Alternative Investment Funds (AIFs) must provide self-declarations and registration certificates issued by respective regulators like IRDAI and SEBI.

For non-resident shareholders, the standard TDS rate is 20% plus applicable surcharge and cess. Those seeking benefits under Double Tax Avoidance Agreements (DTAA) must provide a Tax Residency Certificate, PAN details, and a self-declaration meeting treaty eligibility requirements. The company emphasized it is not obligated to apply beneficial DTAA rates without satisfactory documentation.

Shareholders must submit the necessary documents to determine the appropriate tax rate by 6:00 P.M. on Friday, June 26, 2026. Documents can be emailed to compliance@thyrocare.com or uploaded via the RTA MUFG Intime India Private Limited service request portal. No claims for tax adjustments will be entertained after this deadline.

TDS Rates for Resident Shareholders

TDS Rates for Non-Resident Shareholders